"Pharma Lyophilisation Market Will Reach $2.48 Billion in 2012" Predicts Visiongain Report
A new report by visiongain predicts that the 2012 world market for lyophilisation (freeze drying) products and services for pharma will reach $2.48 billion. That revenue forecast and others appear in Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK.
London, United Kingdom, September 13, 2012 --(PR.com)-- Visiongain predicts that pharmaceutical freeze drying revenues will increase strongly from 2012 to 2022, with many commercial opportunities for those products and services. Through emerging technologies and increasing demand for drugs using lyophilisation, the future of that industry and market holds great promise.
Dr Syed Ahmed, a senior pharmaceutical industry analyst in visiongain, said: “In recent years the market for lyophilisation technology and services has enjoyed strong growth. Key drivers for the sector have been new products and drug classes, especially in biotechnology. We predict that industry and market will continue to expand through greater demand for lyophilisation technologies and services, particularly demand from the expanding industry for injectable therapeutics.
“Our research shows that the world lyophilisation industry and market will benefit from the launch of new biologic drugs and vaccines. For biological drugs, the parenteral route of administration will remain the most important. Lyophilisation is an established method in the formulation of biological products. There are under-met needs for improved stability and cost effectiveness, as well as for more convenience in transport, storage and use of therapeutic agents. Rapid stabilisation, long-term product stability, ease of reconstitution and process advantages for heat-sensitive products will stimulate growth of the lyophilisation technology and services market.”
The new report shows revenue forecasts to 2022 at overall world market, submarket, application and national level. Its research, data and analyses cover activities of GEA Lyophil, Labconco Corporation, Vetter Pharma-Fertigung, Piramal Pharma Solutions (PPS), SP Scientific and other providers of lyophilisation products and services to healthcare.
In addition to forecasting the overall world market for the topic, the analysis predicts revenue trends for world-level submarkets:
• cGMP lyophilisers
• Laboratory lyophilisers
• Lyophilisation services.
Visiongain’s investigation discusses technological and commercial news, shows research interviews and predicts revenues to 2022 in leading national markets. The study analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), India and China.
The report also forecasts sales of drug classes using the drying technologies. Those applications include therapeutic monoclonal antibodies (MAbs), insulins, interferons and vaccines.
Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets for pharmaceutical technologies.
For sample pages and further information concerning the Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022 please visit: http://www.visiongain.com/Report/877/Lyophilisation-for-Pharmaceuticals-Products-and-Services-Market-2012-2022
For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Dr Syed Ahmed, a senior pharmaceutical industry analyst in visiongain, said: “In recent years the market for lyophilisation technology and services has enjoyed strong growth. Key drivers for the sector have been new products and drug classes, especially in biotechnology. We predict that industry and market will continue to expand through greater demand for lyophilisation technologies and services, particularly demand from the expanding industry for injectable therapeutics.
“Our research shows that the world lyophilisation industry and market will benefit from the launch of new biologic drugs and vaccines. For biological drugs, the parenteral route of administration will remain the most important. Lyophilisation is an established method in the formulation of biological products. There are under-met needs for improved stability and cost effectiveness, as well as for more convenience in transport, storage and use of therapeutic agents. Rapid stabilisation, long-term product stability, ease of reconstitution and process advantages for heat-sensitive products will stimulate growth of the lyophilisation technology and services market.”
The new report shows revenue forecasts to 2022 at overall world market, submarket, application and national level. Its research, data and analyses cover activities of GEA Lyophil, Labconco Corporation, Vetter Pharma-Fertigung, Piramal Pharma Solutions (PPS), SP Scientific and other providers of lyophilisation products and services to healthcare.
In addition to forecasting the overall world market for the topic, the analysis predicts revenue trends for world-level submarkets:
• cGMP lyophilisers
• Laboratory lyophilisers
• Lyophilisation services.
Visiongain’s investigation discusses technological and commercial news, shows research interviews and predicts revenues to 2022 in leading national markets. The study analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), India and China.
The report also forecasts sales of drug classes using the drying technologies. Those applications include therapeutic monoclonal antibodies (MAbs), insulins, interferons and vaccines.
Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets for pharmaceutical technologies.
For sample pages and further information concerning the Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022 please visit: http://www.visiongain.com/Report/877/Lyophilisation-for-Pharmaceuticals-Products-and-Services-Market-2012-2022
For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Contact
Visiongain
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Contact
Categories